---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-25-000201"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:59:47.936785+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes

## Summary
- Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).
- Innovative Medicine sales $15,563M (+6.8% operational); MedTech sales $8,430M (+6.8% operational).
- Intends to separate Orthopaedics business into standalone DePuy Synthes; FY2024 ortho sales ~$9.2B.
- Target completion in 18-24 months; Namal Nawana appointed Worldwide President of DePuy Synthes.
- Separation aims to shift MedTech portfolio to higher-growth/margin markets; JNJ retains focus on six growth areas.

## SEC filing metadata
- accession: 0000200406-25-000201
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/0000200406-25-000201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-25-000201
- JSON: https://secwatch.observer/filing/0000200406-25-000201.json
- Plain text: https://secwatch.observer/filing/0000200406-25-000201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.